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ABSTRACT
2,6-Diaminopyridine-3,5-bis(thiocyanate) (PR-619) is a broad-
spectrum deubiquitinating enzyme (DUB) inhibitor that has been
employed in cell-based studies as a tool to investigate the role of
ubiquitination in various cellular processes. Here, we demon-
strate that in addition to its action as a DUB inhibitor, PR-619 is
a potent DNA topoisomerase II (TOP2) poison, inducing both
DNA topoisomerase IIa (TOP2A) and DNA topoisomerase IIb
(TOP2B) covalent DNA complexes with similar efficiency to the
archetypal TOP2 poison etoposide. However, in contrast to etopo-
side, which induces TOP2-DNA complexes with a pan-nuclear
distribution, PR-619 treatment results in nucleolar concentration
of TOP2A and TOP2B. Notably, neither the induction of TOP2-DNA
covalent complexes nor their nucleolar concentration are due to
TOP2 hyperubiquitination since both occur even under conditions
of depleted ubiquitin. Like etoposide, since PR-619 affected TOP2
enzyme activity in in vitro enzyme assays as well as in live cells, we
conclude that PR-619 interacts directly with TOP2A and TOP2B.
The concentration at which PR-619 exhibits robust cellular DUB
inhibitor activity (5–20 mM) is similar to the lowest concentration at
which TOP2 poison activity was detected (above 20 mM), which
suggests that caution should be exercised when employing this
DUB inhibitor in cell-based studies.
Introduction
Ubiquitination is a post-translational modification where
the polypeptide ubiquitin is attached to lysine residues of
substrate proteins. This process is reversible, and ubiquitin
removal is orchestrated by a large family of deubiquitinating
enzymes (DUBs), which fall into six subfamilies based on
sequence and domain similarity (Harrigan et al., 2018). Five
of the subfamilies, which contain the majority of the DUBs,
are cysteine peptidases. Ubiquitination and deubiquitina-
tion together with proteasomal activity control many
aspects of cell physiology, and many of the enzymes involved
have been implicated in human disorders, including cancer.
As a result, they are an important focus of drug development
programs (Huang and Dixit, 2016; Manasanch and Orlowski,
2017; Harrigan et al., 2018). A considerable number of small
molecule inhibitors of specific DUBs are now in preclinical
development (D’Arcy et al., 2015; Harrigan et al., 2018). These
compounds are not only important as potential clinical leads
but provide tools to probe the physiologic functions of
specific DUBs and of ubiquitination in general. While most of
thereported smallmolecule inhibitors exhibit specificity for par-
ticular DUBs, 2,6-diaminopyridine-3,5-bis(thiocyanate) (PR-619)
is a broad-spectrum DUB inhibitor that nonetheless does
not target other cysteine proteases such as cathepsin B or
calpain 1 (Altun et al., 2011). In cell-based assays PR-619
was shown to substantially inhibit the activity of ubiquitin-
specific protease, ubiquitin carboxy-terminal hydrolase, OTU,
andMJD class DUBswhen applied at 20–50 mM, and exhibited
a clear effect at a concentration as low as 5 mM (Altun et al.,
2011). PR-619 has been employed as a tool to investigate the
role of ubiquitination in cellular processes including lysosomal
degradation (Balut et al., 2011), caspase activation (Crowder
et al., 2016), the stability of sirtuin-7 (Pandey and Kumar,
2015), protein aggregate formation (Seiberlich et al., 2012),
human immunodeficiency virus replication (Setz et al., 2017),
and oocyte maturation (Wang et al., 2017), as well as in the
analysis of ubiquitin chain structure (Rana et al., 2017). In
addition, PR-619 also inhibited the de-SUMOylating enzyme
sentrin-specific protease (SENP) 6 in vitro and leads to accu-
mulation of SUMOylated proteins in cells (Altun et al., 2011;
Barry et al., 2018).
As described previously, PR-619 was characterized as a
broad-spectrum DUB inhibitor (Altun et al., 2011). We report
here that in addition to this activity, PR-619 affects DNA
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topoisomerase II (TOP2) and causes the accumulation of abun-
dant DNA topoisomerase IIa (TOP2A) and DNA topoisomerase
IIb (TOP2B) covalent DNA complexes in cells, with similar
efficiency to the classic TOP2 poison etoposide. TOP2 enzymes
alter DNA topology by forming a short-lived enzyme-bridged
DNA double-strand break (DSB), where subunits of the dimeric
TOP2 enzyme remain covalently attached to each end of the
DSB via a 59-phosphotyrosyl linkage. A second DNA seg-
ment then passes through the enzyme-bridged DNA gate,
and finally the break is religated by the enzyme, completing
the reaction cycle. TOP2 poisons, such as etoposide, are used
in anticancer therapies; they inhibit the religation step of
the enzyme’s reaction cycle, resulting in the persistence of
covalently linked TOP2-DNA complexes (Cowell and Austin,
2012), which can be converted to DNADSBs and are cytotoxic.
These covalent complexes can be detected and quantified
using the trapped in agarose DNA immunostaining (TARDIS)
assay (Willmore et al., 1998; Cowell et al., 2011b; Cowell and
Austin, 2018). We demonstrate here that PR-619 induces
TOP2A and TOP2B covalent DNA complexes and redistribu-
tion of TOP2 in the nucleus. Surprisingly, we found that these
effects occurred even under conditions of depleted ubiquitin,
leading us to conclude that they are independent of the DUB
inhibitory activity of PR-619, and thus probably result from
direct interaction with TOP2, interfering with its religation
activity.
Materials and Methods
Reagents and Antibodies. Etoposide and 29,39,49-trihydroxy-flavone
(2-D08) were purchased fromSigma-Aldrich (Dorset, UK); PR-619was
obtained from Tocris Biosciences (Bristol UK); {(1R,2R,3S,4R)-2,3-
dihydroxy-4-[(2-{3-[(trifluoromethyl)sulfanyl]phenyl}pyrazolo[1,5-
a]pyrimidin-7-yl)amino]cyclopentyl}methyl sulfamate (MLN7243)
was obtained fromActive BiochemLtd. (HongKong); and {(1R,2S,4R)-
4-[(5-{[1-(3-bromobenzyl)-1H-pyrazol-3-yl]carbonyl}-4-pyrimidinyl)amino]-
2-hydroxycyclopentyl}methyl sulfamate (ML-792) was obtained from
Bioquote (York, UK). Rabbit anti-TOP2A (4566) and anti-TOP2B
(4555) antibodies were raised in-house to the C-terminal domains
of the respective proteins (Atwal et al., 2019). Anti-ubiquitin FK2
(anti-mono and poly-ubiquitinated conjugates, K29, K48, or K63 linked)
was obtained from Enzo (Exeter, UK), and anti-SUMO2/3 (Ab81371)
was from Abcam (Cambridge UK).
Cell Culture. K562 cells were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin and
streptomycin (Thermo Fisher Scientific, UK). HeLa cells were
cultured in Eagle’s minimum essential medium plus 10% fetal
bovine serum and 1% penicillin and streptomycin (Thermo Fisher
Scientific). K562 (ATCC CCL-243) and HeLa (ECACC 93021013)
cell lines were originally sourced from ATCC and ECACC, respectively.
Cells were cultured at 37°C in a humidified atmosphere containing
5% CO2. Experiments were conducted on cells growing in log phase.
Cells were routinely checked for mycoplasma infection.
Trapped in Agarose DNA Immunostaining Assay. Cells were
exposed for 2 hours to etoposide, PR-619, or an equal volume of DMSO
and were then pelleted and washed in ice-cold PBS. For TARDIS
assays involvingHeLa cells, the cells were first trypsinized and briefly
washed in cold complete cell culture medium. TARDIS assays were
carried out essentially as described previously (Willmore et al., 1998;
Cowell and Austin, 2018). TOP2 covalent complexes were visualized
by immunofluorescence using rabbit anti-TOP2A (4566) or rabbit anti-
TOP2B (4555) antibodies raised to the C-terminal domain of human
TOP2A and TOP2B, respectively, and specific mouse antibodies as
indicated. Secondary antibodies were AlexaFluor 488- or 594-coupled
anti-rabbit or anti-mouse antibodies (ThermoFisher Scientific). Slides
were counterstained with Hoechst 33258 to visualize DNA. Hoechst
and AlexaFluor images were captured using an epifluorescence micro-
scope (Olympus IX-81) fitted with an Orca-AG camera (Hamamatsu)
and suitable narrow band filter sets. For quantitative analysis, images
were captured using a 10X objective. After image capture, automated
slide scoring was performed using Volocity 6.3 software (PerkinElmer
Inc., San Diego, CA) as described previously (Atwal et al., 2019)
using the same parameters for each slide. Data were subsequently
processed and represented using GraphPad Prism 8.2 (Perkin
Elmer) and R. For higher resolution qualitative spatial analysis,
a 40 or 60 objective was used and no blinding was applied.
Image composites were made with Volocity 6.3 and Adobe Photo-
shop, ensuring that image adjustments were constant between
different cell treatments.
Immunofluorescence Analysis Using Paraformaldehyde
Fixed Samples. K562 cells were washed and pelleted in ice-cold
PBS and spotted onto poly-L-lysine reaction well slides (Marienfeld;
VWR, Leicestershire, England). Cells were fixed in 4% formaldehyde
in PBS at room temperature and permeabilized using 120 mM KCl,
20 mMNaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, and 0.1% Triton
X-100 buffer. After blocking in 120 mM KCl, 20 mM NaCl, 10 mM
Tris-HCl pH 8.0, 1mMEDTA, and 0.1%Triton X-100 (plus 2% bovine
serum albumin and 10% dry milk powder) buffer, cells were probed
with primary and secondary antibodies as described for TARDIS.
Slideswere counterstainedwith 4,6-diamidino-2-phenylindole (Vector
Laboratories, Burlingame, CA) and viewed using an epifluorescence
microscope (Olympus IX-81). Atomated analysis and data presentation
were performed as for TARDIS.
Differential Retention of TOP2 Analysis. Differential reten-
tion of TOP2 (DRT) analysis was performed as described previously
(Agostinho et al., 2004; Cowell et al., 2011a). Briefly, HeLa cells were
grown on coverslips and then extracted once on ice in DRT buffer
[30 mM HEPES, 65 mM PIPES, 10 mM EGTA, and 2 mM MgCl2
(pH 6.9), with 350 mM NaCl and 0.5% Triton X-100] containing
protease inhibitors for 30 seconds to 1 minute with occasional gentle
agitation. Cells were then fixed with paraformaldehye and imaged as
described for immunofluorescence.
In Vitro TOP2 Assays. Plasmid DNA cleavage reactions were
performed as described previously (Burden et al., 2001). Each reaction
contained 600 ng of purified TOP2A or TOP2B protein and 6.5 mg
plasmid DNA TCS1 (Lee et al., 1989). Precipitated DNA was resus-
pended in 15 ml of water and 5 ml agarose loading buffer (0.5% SDS,
25% glycerol, and 0.1% bromophenol blue). Samples were heated at 70°C
for 2 minutes before loading onto a 1% Tris-acetate-EDTA agarose gel
and electrophoresed at 45 V in 1 Tris-acetate-EDTA. After running,
gels were stained with ethidium bromide and imaged under UV
transillumination with Bio-Rad Gel Doc EZ Imager. For plasmid
relaxation assays, 10 ng of purified TOP2A or TOP2B protein was
incubated at 37°C for 30 minutes with 1.3 mg supercoiled plasmid
TCS1 in relaxation buffer [50 mM Tris (pH 7.5), 10 mM MgCl2,
0.5 mM EDTA, 30 mg/ml bovine serum albumin, and 1 mM dithio-
threitol) containing 1 mM ATP. Reactions were analyzed by electro-
phoresis in 0.8%Tris-borate-EDTA agarose gel. Gels were stained and
imaged as previously described.
Chromatin Immunoprecipitation. K562 cells were treated with
80mMPR-619, 100 mMetoposide, or DMSO (control) for 2 hours, before
collecting cells by centrifugation and washing twice with ice-cold PBS.
Crosslinking was performed with 1% paraformaldehyde for 5 minutes
on ice and paraformaldehyde was quenched with glycine. Cell pellets
were frozen at 280°C. Pellets were thawed in 5 mM PIPES (pH 8.0),
85 mM KCl, and 0.5% NP40 plus protease inhibitors, and passed
10 times through a 21G syringe needle. Nuclei were pelleted and
resuspended in 1% NP40, 0.5% Na deoxycholate, and 0.1% SDS
in PBS containing protease inhibitors, and chromatin was sonicated
to an average size of approximately 500 base pairs. Chromatin
immunoprecipitation (ChIP) assays were performed with rabbit
anti-TOP2A 4566, rabbit anti-TOP2B 4555, or control rabbit IgG
prebound to protein A Dynabeads (Thermo Fisher Scientific).
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For semiquantitative polymerase chain reaction (PCR) analysis,
cycle numbers were chosen that resulted in near endpoint yield for
inputs (diluted 30 compared with immunoprecipitation samples) but
clearly sub-endpoint yield for the test samples based on product band
intensity and remaining primer visible as a lower band on the agarose
gels. PCRproducts were resolved on 2%agarose gels stainedwithGelRed.
For real-time quantitative PCR, reactions were performed using Ciba
green and a Biorad CFX96 PCR machine using the DDCt method. ChIP
PCR primers have been described previously and were as follows: R-Prom
f-GAGGACAGCGTGTCAGCAATAA, r-GCCCCGGGGGAGGTAT; FY-42
f-CTTTCCGGAGCTCTGCCTAG, r-GGTTGTCGGGCTCCATCT; OS-H4
f-CTCTCCGGAATCGAACCCTGA, r-CGACGACCCATTCGAACGTCT;
OS-H8 f-CCCTTACGGTACTTGTTGACT, r-AGTCGGGTTGCTTG-
GGAATGC; OS-H18 f-GGAAGTTGTCTTCACGCCTGA, r-GTTGAC-
GTACAGGGTGGACTG; Sa-GB f-AAGGTCAATGGCAGAAAAGAA,
r-CAACGAAGGCCACAAGATGTC; Sa-GB f-AAGGTCAATGGCAG-
AAAAGAA, r-CAACGAAGGCCACAAGATGTC (O’Sullivan et al., 2002;
Ray et al., 2013; Yu et al., 2015).
Data Analysis. Statistical analysis was performed using Graph-
Pad Prism 8.2. The details of the tests performed are given in the
figure legends. For signifyingP values, * refers toP, 0.05, ** refers to
P , 0.01, *** refers to P, 0.001, and **** refers to P,0.0001. Error
bars in the bar charts represent the S.D. values. The studywasdesigned
to be exploratory rather than testing a specific null hypothesis;
therefore, the P values are descriptive only. Sample sizes (numbers
of replicate experiments) were specified in advance of data acqui-
sition based on prior knowledge of the characteristics of the assays
involved and anticipating occasional lost or failed samples.
Results
PR-619 Induces TOP2A and TOP2B Covalent DNA
Complexes. TOP2-DNA covalent complexes stabilized by
drugs such as etoposide can be visualized and quantified
using the TARDIS assay, which allows immunofluorescent
analysis after removing cellular proteins, including histones,
by high-stringency extraction of cells embedded in agarose,
leaving nuclear ghosts of genomic DNA in situ (Supplemental
Fig. 1, A–C). We had observed that etoposide-induced TOP2
DNA covalent complexes that are detected using this assay
are accompanied by ubiquitin and SUMO immunofluorescence
signals (Supplemental Fig. 1, B and C). When carrying out
experiments to examine the ubiquitination of TOP2 in cova-
lent DNA complexes, we noticed that the broad-spectrum
DUB inhibitor PR-619 (Altun et al., 2011) itself induced
both TOP2A- and TOP2B-DNA covalent complexes (Fig. 1;
Supplemental Fig. 2, A and B, bottom six panels). As is the
case for etoposide, PR-619 at 40 mM induced an above-
background TOP2A and TOP2B signal in nearly all cells
(Supplemental Fig. 2, A and B). For TOP2A, the median
signal intensity induced by 80 mMPR-619 was approximately
one-half that obtained with 100 mM etoposide, and for TOP2B
the intensity was 75% (Fig. 1). In contrast, at 10 mMPR-619 did
not induce detectable TOP2A complexes (Fig. 1; Supplemental
Fig. 2C). Under standard TARDIS conditions TOP2A com-
plexes are almost undetectable in non-drug-treated cells,
whereas TOP2B reproducibly gives a small above zero signal
in untreated cells; presumably reflecting the capture of endog-
enous TOP2B activity. Although PR-619 induced a clear in-
duction of TOP2B complexes at 20, 40, and 80 mM, little (if any)
increase inTOP2Bsignal above that observed inuntreated cells
was observed in cells treatedwith 10mMPR-619 (Fig. 1,middle
panel; Supplemental Fig. 1C). As described previously, it is
possible to analyze TOP2 post-translational modifications
using the TARDIS assay since the cell lysis and slide process-
ing removes cellular constituents not covalently attached to
genomic DNA. Using pan-ubiquitin antibodies, this revealed
that at least some TOP2-DNA complexes induced by etoposide
are ubiquitinated (Supplemental Figs. 1B and 2). Cells treated
with 20, 40, or 80 mM PR-619 exhibited a much higher
ubiquitin signal than those treated with etoposide (Fig. 2,
right panel; Supplemental Fig. 2), consistent with the activity
of PR-619 as aDUB inhibitor. This leads to the conclusion that
for complexes induced by PR-619 a higher proportion of the
TOP2molecules are ubiquitinated or that each TOP2 complex
is ubiquitinated to a greater extent than those induced by
etoposide. Notably, even at 10mMPR-619 some cells exhibited
a high ubiquitin signal, although most nuclei remained at the
untreated level (Supplemental Fig. 1C, right panel). This is
surprising given that at this concentration PR-619 induced
little (if any) additional TOP2A or TOP2B fluorescence above
that observed in untreated cells but could be explained if
10 mM PR-619 treatment results in hyperubiquitination
of endogenous (i.e., nondrug-induced) TOP2B complexes.
Thus, PR-619 behaves as an effective TOP2poison, at a similar
dose range as etoposide.
Fig. 1. PR-619 induces TOP2 complexes in K562 cells with similar efficiency as etoposide, and complex formation is not dependent on ubiquitination.
Cells were treated with PR-619, etoposide, or solvent control. Where indicated, cells were also treated with the E1 UEA inhibitor MNL7243 (10 mM) prior
to adding etoposide or PR-619. Cells were embedded in agarose on microscope slides and processed by TARDIS analysis for TOP2A, TOP2B, and
ubiquitin. Bar graphs represent the mean of the median values derived from replicates, which are also indicated individually as blue-lined circles. Error
bars represent the S.D. MNL7243 pretreatment was for 2 hours. Statistical analysis was performed using t tests. For the last column in the left and right
panel highlighted ($ for the PR-619 concentration), cells were treated with 80 mMPR-619 and processed with other samples, but with the omission of the
primary antibody during immunofluorescence, to test for autofluorescence originating in the sample.
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Induction of TOP2 DNA Covalent Complexes by
PR-619 Is Not due to Hyperubiquitination of TOP2.
Since PR-619 is a broad range DUB inhibitor and treatment
with PR-619 resulted in bright labeling of nuclear ghosts with
anti-ubiquitin as well at TOP2 antibodies (Fig. 1, right panels;
Supplemental Fig. 1, B and C), we hypothesized that the
induction of TOP2-DNA complexes by PR-619 could be linked
to its DUB inhibitory activity. To test this hypothesis, we
pretreated cells with the E1 ubiquitin-activating enzyme
inhibitor MLN7243 at a dose and time previously shown to
cause a loss of polyubiquitin chains and monoubiquitinated
histone H2A in cells (Hyer et al., 2018). As expected, this pre-
treatment greatly reduced the accumulation of ubiquitin in
nuclear ghosts formed from PR-619–treated cells (Fig. 1, right
panel). However, contrary to expectations, ubiquitin depletion
by MLN7243 had no significant effect on PR-619–induced
TOP2A or TOP2B complexes. MLN7243 did not induce TOP2-
DNA complexes on its own, and also had no effect on etoposide-
induced TOP2-DNA complex formation (Fig. 1, left andmiddle
panels). Thus, PR-619 acts as a TOP2 poison independently
of the effects of DUB inhibition. This conclusion is supported
by in vitro enzyme assays, where like etoposide PR-619 stim-
ulated TOP2A and TOP2B plasmid cleavage activity and
inhibited decatenation activity (Fig. 2).
Etoposide treatment results in SUMO2/3 accumula-
tion that coincides with TOP2 signal in the TARDIS assay
(Schellenberg et al., 2017; Lee et al., 2018) (Supplemental
Fig. 1C). Since PR-619 has been shown to inhibit SENPs
(Altun et al., 2011), we were interested in determining
whether PR-619 induced a proportionally greater level of
SUMOylated protein-DNA covalent complexes. As shown
in Supplemental Fig. 3, A–C, PR-619 did induce a robust
SUMO2/3 signal, which coincided with the nuclear signal
intensity observed for TOP2A and TOP2B, consistent with the
presence of SUMOylated TOP2 complexes. However, we were
not able to efficiently suppress the level of SUMOylation
induced by PR-619 using small molecule inhibitors 2-D08 or
ML-792, which affect the transfer of SUMO from E2 enzyme
UBC9 or SAE1 activity, respectively (Kim et al., 2013; He
et al., 2015).
Fig. 3. PR-619–induced TOP2 complexes are unevenly distributed in the nucleus. Cells were treated with PR-619, etoposide, or solvent control (DMSO)
for 2 hours and TOP2 complexes were detected using the TARDIS assay. Immunofluorescence was performed using anti-TOP2A (A) or anti TOP2B
(B) antibodies and anti-ubiquitin (FK2). Images were acquired using a 40X objective and are extended focus widefield images. Enlarged nuclei indicated
by asterisk; scale bar, 10 mm.
Fig. 2. PR-619 inhibits TOP2-induced DNA cleavage and relaxation of supercoiling in vitro. (A) Etoposide and PR-619 induce plasmid cleavage by
TOP2A or TOP2B. Plasmid cleavage was carried out with 600 ng recombinant TOP2A (top) or 600 ng of recombinant TOP2B (bottom). Positions of nicked
(N), linear (L), and supercoiled plasmid (SC) are denoted on the left. Linearized plasmid cleaved with EcoR1 is shown in lane 1. Substrate only and
substrate with TOP2 (1T2) are shown in lanes 2 and 3, respectively. As a control, reactions with 1 ml DMSO (lane 4) and 2 ml DMSO (lane 13) are shown.
(B) Etoposide and PR-619 inhibited plasmid relaxation by TOP2A and TOP2B. Plasmid relaxation was carried out with 10 ng TOP2A (top) or 10 ng
TOP2B (bottom). The positions of nicked (N), relaxed (R), and supercoiled plasmid (SC) are denoted on the left. Substrate only and substrate with TOP2
(1T2) are shown in lanes 1 and 2, respectively. As a control, reactions with 1 ml DMSO (lane 3) and 2 ml DMSO (lane 12) are included.
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PR-619 Induced TOP2A and TOP2BCovalent Complexes
that AreUnevenlyDistributed in theNucleus. We routinely
observe that etoposide and other established TOP2 poisons
such as mitoxantrone induce TOP2A and TOP2B fluores-
cence signal throughout the volume of the nuclear ghosts
in the TARDIS assay, although this can appear slightly
granular for TOP2B under higher magnification widefield
microscopy (Fig. 3). However, in most cells PR-619 induced
a different distribution of TOP2A and TOP2B fluorescent
signal consisting of large foci of signal (Fig. 3). The FK2 ubiquitin
fluorescent signal partially overlapped that of both TOP2A and
TOP2B (Fig. 3), as did that for SUMO2/3 (Supplemental Fig. 3A),
consistent with the conclusion that the bright ubiquitin and
SUMO signals originate from ubiquitinated and SUMOylated
TOP2 trapped as covalent-DNA complexes.
PR-619 Drives Ubiquitin-Independent Nucleolar
Localization of TOP2A and TOP2B. Historically, there
has been some disagreement regarding the subnuclear distri-
bution of pools of TOP2, especially TOP2B, probably due to
the use of cells from different species, antibodies, and fixation
conditions (Chaly and Brown, 1996; Onoda et al., 2014; Austin
et al., 2018). The consensus, in agreement with our own
observations, is that TOP2 is mobile in the interphase
nucleus and is distributed throughout the nucleoplasm
Fig. 4. PR-619 drives nucleolar localization of TOP2A
and TOP2B. K562 cells were treated with PR-619 (80 mM),
and where indicated were pretreated with the ubiquitin-
activating enzyme inhibitor MLN7243 (10 mM, 2 hours),
fixed with paraformaldehyde, and analyzed by immunoflu-
orescence for TOP2A (A) or TOP2B (B) and the nucleolar
marker fibrillarin. (C) K562 cells were treated as in (A and
B) and stained for ubiquitin (FK2) and TOP2A. Images are
shown as extended focus projections using 0.1 mm z-steps
and representative images obtained from several fields of
cells from duplicate slides; scale bar, 10 mm.
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with some distribution in the nucleoli. In addition, we have
also observed a concentration of TOP2B in the abundant
perinucleolar heterochromatin of mouse cells (Cowell
et al., 2011a). Thus, we were interested to determine whether
the uneven focal distribution of PR-619–induced TOP2A and
TOP2B-DNA complexes in TARDIS assays reflected nucle-
olar concentration of TOP2. The harsh lysis conditions
employed in the TARDIS assay remove proteinaceous
nuclear structures, precluding costaining for nucleolar
markers such as fibrillarin or pol I. Therefore, we examined
the distribution of TOP2A and TOP2B in PR-619–treated
K562 cells by standard immunofluorescence using para-
formaldehyde fixation at room temperature. Under these
fixation conditions both TOP2A and TOP2B display a fairly
even nucleoplasm staining pattern in the majority of in-
terphase cells. In contrast, in PR-619–treated cells TOP2A
and TOP2B became concentrated in a few large nuclear
foci, reminiscent of the pattern observed under TARDIS
conditions (Figs. 3 and 4, A and B). Costaining for TOP2A or
TOP2B and fibrillarin confirmed that the large focal TOP2
clusters in PR-619 colocalized with nucleoli (Fig. 4B). PR-
619 induced a large increase in overall protein ubiquitina-
tion, as detected using antibody FK2 in paraformaldehyde
fixed cells, but prior treatment with the ubiquitin-activating
enzyme inhibitor MLN7243 resulted in almost complete loss
of FK2 signal, even in PR-619–treated cells (Fig. 4C).
However, the PR-619–associated nucleolar redistribution
of TOP2 was not affected by prior treatment with
MLN7423. Thus, the nucleolar redistribution of TOP2A
and TOP2B in PR-619–treated cells does not appear to be
dependent on hyperubiquitination of the enzymes.
Sites of TOP2 activity can be visualized using theDRT assay
(Agostinho et al., 2004), in which adherent cells grown on
coverslips are extracted with salt and detergent to enrich for
active TOP2molecules that are trapped onDNA. Since overall
nuclear architecture is better conserved by DRT assay than in
the TARDIS assay, this method was used to examine the
nuclear distribution of active TOP2A and TOP2B in HeLa
cells. In the absence of added drug, most TOP2A and TOP2B
were lost from the cells, as expected (Supplemental Figs. 4 and
5, top rows). However, PR-619 treatment led to the formation
of focal concentrations of both TOP2A and TOP2B correspond-
ing to the location of nucleoli as judged from the 4,6-diamidino-
2-phenylindole staining pattern. In contrast, but consistent
with previous observations, etoposide induced an essentially
pan-nuclear TOP2A pattern and a fine granular pattern
with TOP2B. Thus, PR-619 traps TOP2A and TOP2B in the
nucleolar compartment of the epithelial cells (HeLa) as
well as lymphoblastoid cells (K562). To be trapped and
stable to extraction, TOP2 must presumably be active in the
nucleolar compartment of PR-619–treated cells. Notably,
Onoda et al. (2014) demonstrated that a pool of TOP2B is
localized in the nucleolar regions in live cells and after
fixing with formaldehyde at 37°C, but redistributes to the
nucleoplasm if cells are cooled; these authors report that
this nucleolar pool is largely inactive and bound to RNA. To
determine whether TOP2 is concentrated in the nucleolar
domain via RNA interactions in PR-619–treated cells, K562
cells were treated with PR-619 or etoposide and TOP2 com-
plexes were visualized and quantified using the TARDIS assay
after treating extracted agarose-embedded cells with RNase
A. Notably, RNase treatment made no difference to either the
Fig. 5. Combined etoposide and PR-619 treatment. K562 cells were treatedwith etoposide or PR-619 individually for 150minutes, with both for 150minutes or
with either one of the drugs first for 30minutes before adding the other drug for 120minutes and then collecting the cells for TARDIS analysis. (A) Quantitative
analysis of TARDIS samples as described for Fig. 1. (B) Representative nuclei from extended focus images acquired at higher magnification.
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qualitative distribution or the intensity of the TOP2A or
TOP2B signals (Supplemental Fig. 6).
Since etoposide and PR-619 induce TOP2-DNA complexes
with different distributions in the nucleus, we carried out
combination experiments to determine whether complex forma-
tion would be quantitatively (in the overall level of complexes
formed) or qualitatively (in the distribution of TOP2 complexes in
the nucleus) additive. Using both drugs at concentrations that
individually generate similar levels of TOP2 complexes (50 mM
etoposide and 80 mM PR-619), we found that for TOP2B the
combination of both drugs resulted in approximately 30% larger
signal than either drug alone, whether the drugs were added
simultaneously or sequentially (Fig. 5A). For TOP2A, the
combination resulted in only a marginal increase in signal
compared with PR-619 alone (Fig. 5A). Thus, there is some
additive effect, particularly for TOP2B, but this may have
been limited by saturating effects at the concentrations of
drugs used. While etoposide and PR-619 treatment resulted
in different distributions of TOP2A andTOP2Bwithin nuclear
ghosts (Fig. 5B) combined treatment with both drugs resulted
in TOP2A and TOP2B complex distributions very similar to
that obtained with PR-619 alone (Fig. 5B; Supplemental Figs.
7 and 8). In particular, pretreatment with etoposide did not
noticeably prevent the focal distribution associated with PR-
619, suggesting that a sufficient pool of untrapped TOP2
remains after 50mMetoposide treatment to subsequently give
rise to the focal PR-619–derived pattern of TOP2 complexes.
Also of note, pretreatment with 5 mM PR-619, sufficient to
inhibitDUBandSENPactivity (Altunet al., 2011) but insufficient
to generate TOP2-DNA complexes, did not affect the distribution
of TOP2 complexes induced by etoposide.
TOP2A and TOP2B Associate with Recombinant
DNA Repeats. Given thatPR-619 treatment leads to nucleolar
retention of TOP2 (Fig. 4) and induces TOP2-DNA complexes
that appear to coincide with nucleolar-derived regions in
TARDIS and DRT assays, we set out to determine whether
PR-619 drives TOP2 associationwith ribosomal DNA (rDNA)
repeats. Notably, previous studies have demonstrated that
TOP2B is present across at least some rDNA repeat units by
ChIP sequencing (Uusküla-Reimand et al., 2016) and that
TOP2A associates with and promotes the activity of pol I
at rDNA promoters (Ray et al., 2013). We performed ChIP
analysis with brief formaldehyde crosslinking, utilizing PCR
primers corresponding to the rDNA promoter, 18S, and 28S
coding regions and the spacer region (Fig. 6A). Under control
conditions TOP2A and TOP2B could be detected at each of
these locations using semiquantitative PCR, but the signal
was more robust with either TOP2 poison, particularly with
PR-619 (Fig. 6B). This was confirmed by quantitative PCR
for two of the locations (promoter and 28S) (Fig. 6C). Thus,
PR-619 does appear to lead to increased association of TOP2A
and TOP2B with rDNA. For comparison, we examined the
association of TOP2with satellite DNA (some of which occupies
a perinucleolar position in the nucleus) using an alpha satellite
PCR primer pair. We observed a robust TOP2A and TOP2B
ChIP signal under each condition but did not observe addi-
tional PR-619–mediated accumulation for alpha satellite DNA
(Fig. 6B).
PR-619 Efficiently Induces Histone H2AX Phosphor-
ylation. Cellular processing of TOP2-DNA complexes via
proteasomal destruction and other mechanisms leads to the
appearance of protein-free DSBs, which are otherwise
Fig. 6. PR-619 treatment leads to enhanced association of TOP2A and TOP2B with rDNA. (A) Representation of the human rDNA repeat unit showing
promoter (arrow), coding sequence (thick line), CTCF site (red bar), and PCR primers. (B) Semiquantitative PCR fromChIPDNA samples from untreated
(control), PR-619–treated, and etoposide-treated K562 cells. Track M: 100 and 200 base pair markers; input5 1/30 dilution of input chromatin used for
immunoprecipitation, IgG control, and rabbit IgG. Primer pair names and the number of PCR cycles are indicated on the right. (C) Quantitative real-time
PRC analysis for primers R-prom (promoter) and OS-H8 coding region corresponding to 28S RNA.
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concealed by TOP2 protein and do not elicit a DNA damage
response (Mårtensson et al., 2003; Zhang et al., 2006; Fan
et al., 2008; Schellenberg et al., 2017; Lee et al., 2018). As
a proxy for DSBs, we measured the appearance of phospho-
histone H2AX (gH2AX) in K562 cells treated with etoposide
or PR-619. Both etoposide and PR-619 induced robust H2AX
phosphorylation at doses that efficiently trap TOP2 in
covalent-DNA complexes (Fig. 7; Supplemental Fig. 9).
However, comparing equal doses of PR-619 and etoposide,
PR-619 exhibited a much steeper dose response than etopo-
side, producing little gH2AX in most cells at 20 mM and
background levels at 5 and 10 mM.
PR-619 Induces Persistent TOP2-DNA Complexes.
The resolution of poison-induced TOP2-DNA covalent com-
plexes in cells after drug washout can be followed using
TARDIS, immunocomplex of enzyme, or potassium-SDS
precipitation assays (Hsiang and Liu, 1989; Errington et al.,
2004; Nitiss et al., 2012; Schellenberg et al., 2017). In cultured
mammalian cells, the half-life of etoposide-induced TOP2A
and TOP2B complexes is less than an hour (Errington et al.,
2004; Schellenberg et al., 2017).However, the observed reversal
rate differs for different TOP2 poisons. While the mAMSA
reversal rate is similar to etoposide, it is much longer for
mitoxantrone (Fox and Smith, 1990; Willmore et al., 2002),
and in the case of the anthracycline idarubicin, we observed
TOP2-covalent DNA complexes increase for up to 48 hours
after drug washout (Errington et al., 2004). To determine the
longevity of PR-619–-induced TOP2 complexes, K562 cells
were incubated with etoposide or PR-619 for 2 hours as
before, and then collected for TARDIS analysis before and
after drug washout (1 hour) and replated in fresh medium.
In line with the rapid reversal of etoposide-induced TOP2
DNA complexes observed previously, most of the etoposide-
induced TOP2A signal was lost and the TOP2B complexes
returned to background levels following drug washout. In
contrast, in K562 cells treated with PR-619, TOP2A and
TOP2B signals increased significantly following drug wash-
out, while the ubiquitin signal was maintained (Fig. 8). The
reason for the persistence of the PR-619–induced complexes
could include slower cellular processing of these complexes
compared with those induced by etoposide; however, the
appearance of abundant gH2AX (similar to the signal obtained
with 50mMetoposide) during the 2-hour drug incubation period
(Fig. 7; Supplemental Fig. 9) indicates that a substantial
fraction of PR-619–induced TOP2 complexes are processed
to reveal protein-free breaks during this period. Alterna-
tively, greater retention of PR-619 in K562 cells following
drug washout could lead to persistence of TOP2-DNA
complexes, an explanation that has been suggested for
the persistence of mitoxantrone- and idarubicin-induced
TOP2-DNA complexes (Willmore et al., 2002; Errington
et al., 2004). In this scenario, significant PR-619 is retained
in cells during drug washout, resulting in continued formation
of new TOP2-DNA complexes even as the initial complexes
are processed to DSBs. In support of this, the yellow color of
PR-619 was clearly visible in cell pellets of PR-619–treated
cells after washing with PBS.
Fig. 7. PR-619 induces histone H2AX phosphorylation. (A and B) K562
cells were treated with etoposide (50 mM) or PR-619 (80 mM) for 2 hours,
fixed with paraformaldehyde, and TOP2A or TOP2B and gH2AX were
detected by immunofluorescences. Images are representative examples
from three replica experiments. (C) H2AX phosphorylation per
nucleus was assessed by quantitative immunofluorescent. Data represent
mean6 S.D., individual data points are indicated as blue-lined circles; scale
bar, 10 mm.
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Discussion
We have demonstrated that PR-619, a previously charac-
terized broad-spectrum DUB inhibitor (Altun et al., 2011), is
also a TOP2 poison, inducing TOP2A and TOP2B DNA com-
plexes with similar potency to the archetypal and clinically
important TOP2 poison etoposide. Established TOP2 poisons
fall into a number of chemical classes including podophyllo-
toxins such as etoposide and teniposide, the anthraciendiones
mitoxantrone and pixantrone, anthracyclines such as idarubi-
cin, acridines including mAMSA, and the quinolone Voreloxin
(Pommier et al., 2010). However, PR-619 is chemically dis-
tinct from each of these classes of TOP2 poison. TOP2-DNA
complexes induced by PR-619 were highly ubiquitinated.
However, TOP2-DNA covalent complexes were formed in
PR-619–treated cells even in the presence of the ubiquitin-
activating enzyme inhibitor MLN7243, although the level
of ubiquitination of the complexes was much lower in
MLN7243 pretreated cells. Thus, it does not appear that
hyperubiquitination of TOP2A or TOP2B is a prerequisite
for the formation of TOP2-DNA complexes. In a previous
study using HCT-116 cells (Hyer et al., 2018), and as demon-
strated here in K562 cells (Fig 4C), MLN7243 caused a very
large reduction in protein ubiquitination within 2 hours
(the length of preincubation employed in this study). There-
fore, it is unlikely—although it cannot be fully excluded—that
Fig. 8. PR-619–induced TOP2 complexes persist after drug washout. K562 cells were incubated in the presence of etoposide (40 mM), PR-619 (80 mM), or
solvent (DMSO) for 2 hours. Cells were either collected immediately or drug was washed out and cells were replated and incubated for a further 1 hour
before collection for TARDIS analysis. (A) Quantification of TARDIS data obtained using anti-TOP2A (4566), anti-TOP2B (4556), and anti-ubiquitin
(FK2) antibodies. Median-integrated fluorescence per nucleus values were normalized to the mean of the medians obtained with each drug directly after
2-hour incubation (i.e., without washout). Data are shown as mean6 S.D. values, and values from individual replicas are indicated as blue-lined circles.
Statistical analysis, the normalized mean integrated fluorescence for PR-619 before and after washout were compared by unpaired t test.
(B) Representative images from TARDIS slides used to produce part A.
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hyperubiquitination of another protein interferes with nor-
mal TOP2 activity leading to TOP2-DNA complex formation.
We found TOP2 complexes induced by etoposide are deco-
rated with SUMO2/3 in addition to ubiquitin (Supplemental
Figs. 1C and 3), as observed previously (Agostinho et al., 2008;
Schellenberg et al., 2017; Lee et al., 2018); however, the
intensity of SUMO staining was greater in PR-619–treated
cells, consistent with the activity of the inhibitor against
SENPs. Thus, it is plausible that PR-619 induces TOP2
complexes via hyper-SUMOylation of the enzymes or an-
other cellular component. We were unable to fully exclude
this possibility in cell-based studies since pretreatment
with either 2-D08 or ML-792 did not substantially affect
the SUMO2/3 signal induced in nuclear ghosts by PR-619
(Supplemental Fig. 3). However, since PR-619 induced DNA
cleavage and inhibited relaxation activities of TOP2A and
TOP2B in in vitro cleavage assays (Fig. 2) PR-619–induced
formation of TOP2A and TOP2B-DNA complexes in cells is
likely to be a direct action on TOP2 enzyme activity. In
addition to inducing TOP2-DNA complexes, PR-619 uniquely
caused a redistribution of TOP2 into the nucleolar compart-
ment, observed by standard immunofluorescence employing
paraformaldehyde fixation and in TARDIS imaging. This
phenomenon occurred even when cells were pretreated with
MLN7243, and thus also appears to be independent of the
DUB inhibitor activity of PR-619. However, for the reasons
described previously, we are not able to exclude the possibility
that hyper-SUMOylation of TOP2 contributes to its nucleolar
accumulation. Although, arguing against this, we observed
that PR-619 at a concentration (5–10 mM) that achieves
efficient DUB and SENP inhibition in cells (Altun et al.,
2011) did not affect the diffuse nuclear distribution of
etoposide-induced TOP2-DNA complexes (Fig. 5). Notably,
SUMOylation of TOP2 is associated with targeting to
mitotic chromosomes (Azuma et al., 2005; Agostinho et al.,
2008), and artificial fusion of poly-SUMO to yeast Top2 results
in nucleolar targeting (Takahashi and Strunnikov, 2008).
Although TOP2A and TOP2B are found throughout the inter-
phase nucleus by immunofluorescence in fixed cells they are
both components of the nucleolar proteome (Andersen et al.,
2005). In addition, protein interactions between TOP2B and
a number of nucleolar proteins have been demonstrated
(Uusküla-Reimand et al., 2016) and live cell imaging revealed
a dynamic and more nucleolar distribution of TOP2A and
TOP2B GFP fusion proteins (Christensen et al., 2002; Onoda
et al., 2014). Thus, it is reasonable to conclude that PR-619
influences the normal distribution of TOP2 between the
nucleoplasm and nucleoli, although the mechanism behind
this is currently unclear. Notably, to form complexes re-
sistant to extraction in TARDIS and DRT assays TOP2A and
TOP2B must be enzymatically active in the nucleolar
compartment in PR-619–treated cells. TOP2A and TOP2B
have been reported to associate with rDNA sequences, and
in ChIP-sequencing analysis TOP2B occupancy was evident
across the rDNA repeat unit coding region and at the promoter
and adjacent CTCF binding region (Ray et al., 2013; Uusküla-
Reimand et al., 2016). Although we could detect TOP2A and
TOP2B at the promoter and coding regions of the rDNA repeat
unit in untreated cells even with the relatively mild cross-
linking conditions employed (Fig. 6B), ChIP efficiency was
greater when TOP2 was trapped on DNA by etoposide, or
PR-619, but this effect was more robust in the case of
PR-619 (Fig. 6, B and C). This is consistent with PR-619
resulting in abundant TOP2-DNA complexes within rDNA
repeat units, although our evidence suggests that these
complexes are distributed across the locus.
PR-619 has become a useful tool in order to probe the role of
ubiquitination in various cell biologic systems (Balut et al.,
2011; Seiberlich et al., 2012; Pandey and Kumar, 2015;
Crowder et al., 2016; Rana et al., 2017; Wang et al., 2017);
however, the work here suggests that some caution should
be applied when using this inhibitor in cell line–based
studies. We have observed that at concentrations 20 mM
and above, PR-619 induces TOP2-covalent DNA complexes
in K562 cells that are converted to DNA double-strand
breaks. Notably, the concentration range where we have
observed pronounced TOP2 poison activity and gH2AX
induction in K562 cells (20–80 mM) is higher than the lowest
concentrations for which PR-619 has demonstrated robust
DUB inhibitory activity (5–20 mM) and growth inhibitory
activity (IC50 ∼2 mM) in HEK 293T cells (Altun et al., 2011).
Thus, the additional TOP2 poisoning property of PR-619 can
be avoided by careful consideration of concentration.
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